Company: KROS
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001664710-25-000046
Chunk: 198

Company: Keros Therapeutics, Inc.
Filing Date: 2025-05-06
Form: 10-Q
Item: Item 8
Chunk 198
---
 or are eligible to receive under our license agreements with each of The General Hospital Corporation, Takeda and Hansoh; 

■the number of potential new product candidates we identify and decide to develop; 

■the need for additional or expanded preclinical studies and clinical trials beyond those that we plan to conduct with respect to our current and future product candidates; 

■the costs involved in growing our organization to the size needed to allow for the research, development and potential commercialization of our current or any future product candidates; 

■the costs involved in filing patent applications, maintaining and enforcing patents or defending against infringement or other claims raised by third parties; 

■the maintenance of our existing license and collaboration agreements and the entry into new license and collaboration agreements; 

■the time and costs involved in obtaining regulatory approval for our product candidates and any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of our product candidates; 

■the effect of competing technological and market developments;

■the cost of manufacturing cibotercept, KER-065, elritercept and future product candidates for clinical trials in preparation for marketing approval applications and in preparation for commercialization; 

■the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products, if approved, on our own; 

■the amount of revenues, if any, we may derive either directly or in the form of royalty payments from future sales of our product candidates, if approved; and 

■market acceptance of any approved product candidates.

We do not have any committed external source of funds or other support for our development efforts and we cannot be certain that additional funding will be available on acceptable terms, or at all. Further, in the event that the license agreement we entered into with Takeda, or the Takeda Agreement, is terminated, we may not receive any additional fees or milestone payments under that agreement. Absent the funding support obtained under the Takeda  Agreement, our further development of elritercept would require significant additional capital from us, or the establishment of alternative collaborations with third parties, which may not be possible. Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private 

32

equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. 

Our ability to